Frequency of homozygous deletion at p16/CDKN2 in primary human tumours

Nature Genetics

Volumn 11, Issue 2, 1995, Pages 210-212

  Cairns, Paul ^a   Polascik, Thomas J ^a,b   Eby, Yolanda ^a   Tokino, Kaori ^a   Califano, Joseph ^a   Merlo, Adrian ^a   Mao, Li ^a   Herath, John ^c   Jenkins, Robert ^c   Westra, William ^b   Rutter, Joni L ^d   Buckler, Alan ^d   Gabrielson, Edward ^b   Tockman, Mel ^e   Cho, Kathleen R ^b   Hedrick, Lora ^b   Bova, G Steven ^b   Isaacs, William ^b   Koch, Wayne ^a   Schwab, Donna ^a   Sidransky, David ^a   more..

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS HOSPITAL   (United States)

^c MAYO CLINIC   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLELE; ARTICLE; BLADDER TUMOR; BREAST CANCER; CANCER GENETICS; GENE DELETION; HOMOZYGOSITY; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MOLECULAR CLONING; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSTATE CANCER;

BLOTTING, SOUTHERN; CHROMOSOME DELETION; CHROMOSOME MAPPING; CHROMOSOMES, HUMAN, PAIR 9; DNA PROBES; DNA, NEOPLASM; DNA, SATELLITE; FEMALE; GENES, TUMOR SUPPRESSOR; GENETIC MARKERS; HOMOZYGOTE; HUMAN; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; NEOPLASMS; POLYMERASE CHAIN REACTION; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0029091503     PISSN: 10614036     EISSN: 15461718     Source Type: Journal    
DOI: 10.1038/ng1095-210     Document Type: Article

References (29)

1. Diaz, M.O. et al. Deletions of interferon genes in acute lymphoblastic leukemia. N. Engl. J. Med. 332, 77-82 (1990).
2. Fountain, J.W. et al. Homozygous deletions within human chromosome band 9p21 in melanoma. Proc. natn. Acad. Sci. U.S.A. 89, 10557-10561 (1992).
3. James, C.D. et al. Chromosome 9 deletion mapping reveals interferon a and interferon β-1 gene deletions in human glial tumors. Cancer Res. 51, 1684-1688 (1991).
4. Olopade, O.I. et al. Homozygous loss of the interferon genes defines the critical region on 9p that is deleted in lung cancers. Cancer Res. 53, 2410-2415 (1993).
5. Cairns, P., Tokino, K., Eby, Y. & Sidransky, D. Homozygous deletions of 9p21 in primary human bladder tumors detected by comparative multiplex polymerase chain reaction. Cancer Res. 54, 1422-1424 (1994).
6. van der Riet, P. et al. Frequent loss of chromosome 9p21 -22 early in head and neck cancer progression. Cancer Res. 54, 1156-1158 (1994).
7. Kamb, A. et al. A cell cycle regulator potentially involved in genesis of many tumor types. Science 264, 436-440 (1994).
8. Nobori, T. et al. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 368, 753-756 (1994).
9. Knudson, A.G., Jr., Hethcote, H.W. & Brown, B.W. Mutation and childhood cancer: a probabilistic model for the incidence of retinoblastoma. Proc. natn. Acad. Sci. U.S.A. 72, 5116-5120 (1975).
10. Hussussian, C.J. et al. Germline p16 mutations in familial melanoma.Nature Genet. 8, 15-21 (1994).
11. Mori, T. et al. Frequent somatic mutation of the MTS1/CDK4I (multiple tumor suppressor/cyclin-dependent kinase 4 inhibitor) in esophageal squamous cell carcinoma. Cancer Res. 54, 3396-3397 (1994).
12. Caldas, C. et al. Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nature Genet 8, 27-32 (1994).
13. Hayashi, N., Sugimoto, Y., Tsuchiya, E., Ogawa, M. & Nakamura, Y. Somatic mutations of the MTS1 (multiple tumor suppressor) CDK41 (cyclin-dependent kinase-4 inhibitor) gene in human primary non-small cell lung carcinomas. Biochem. biophys. Res. Commun. 202, 1426-1430 (1994).
14. Kamb, A. et al. Analysis of the p16 gene (CDKA/2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nature Genet. 8, 23-26 (1994).
15. Xu, L. et al. Rarity of somatic and germline mutations of the cyclin-dependent kinase 4 inhibitor gene, CDK4I, in melanoma. Cancer Res. 54, 5269-5272 (1994).
16. Zhou, X. et al. The MTS1 gene is frequently mutated in primary human esophageal tumors. Oncogene 9, 3737-3747 (1994).
17. Okamoto, A. et al. Mutations in the p16(INK4)/MTS1/CDKN2, p15(INK4B)/ MTS2, and p18 genes in primary and metastatic lung cancer. Cancer Res. 55, 1448-1451 (1995).
18. Cairns, P. et al. Rates of p16(MTS1) mutations in primarytumors with 9p loss. Science 265, 415-416 (1994).
19. Xu, L., et al. Mutational analysis of CDKN2 (MTS1/P16INK4) in human breast carcinomas. Cancer Res. 54, 5262-5264 (1994).
20. Jen, J. et al. Deletion of p16 and p15 genes in brain tumors. Cancer Res. 54, 6353-6358 (1994).
21. Middleton-Price, H., Spurr, N., Hall, A. & Malcolm, S. N-ras-like sequences on chromosomes 9,6 and 22 with a polymorphism at the chromosome 9 locus. Ann. hum. Genet. b, 189-195 (1988).
22. Sauter, G. et al. Chromosome-9 loss detected by fluorescence in situ hybridization in bladder cancer. Int. J. Cancer 64, 99-103 (1995).
23. Kamb, A., Liu, Q., Harshman, K. & Tavtigian, S. Rates of p16(MTS1) mutations in primary tumors with 9p loss. Science 265, 416-417 (1994).
24. Lefebvre, S. et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell 80, 155-165 (1995).
25. Roy, N. et al. The gene for neuronal apoptosis inhibitory protein is partially deleted in individuals with spinal muscular atrophy. Cell 80, 167-178 (1995).
26. Cairns, P., Shaw, M.E. & Knowles, M.A. Initiation of bladder cancer may involve deletion of a tumor suppressor gene on chromosome 9. Oncogene 8, 1083-1085 (1993).
27. Merlo, A., et al. CpG island methylation is associated with transcriptional silencing of the tumour suppressor CDKN2/p16 in human cancers. Nature Med. 1, 686-692 (1995).
28. Weaver-Feldhaus, J. et al. Localization of a putative tumor suppressor gene by using homozygous deletions in melanomas. Proc. natn. Acad. Sci. U.S.A. 91, 7563-7567 (1994).
29. Zhang, J., Meltzer, P., Jenkins, R., Guan, X.Y., Trent, J. Application of chromosome microdissection probes for elucidation of BCR-ABL fusion and variant Philadelphia chromosome translocations in chronic myelogenous leukemia. Blood 81, (12), 3365-3371 (1993).